Crosson C E, Petrovich M
Department of Ophthalmology and Visual Sciences, Texas Tech University Health Sciences Center, Lubbock, USA.
Invest Ophthalmol Vis Sci. 1999 Aug;40(9):2054-61.
Epinephrine is an effective drug for glaucoma treatment. However, the mechanisms responsible for the ocular hypotensive action of this compound are not completely understood. Adenosine is an autacoid released by all cells. This study evaluated the role of adenosine receptor activation in epinephrine-induced changes in ocular function.
Rabbits were pretreated topically with the moderately selective adenosine A1 antagonist 8-(p-sulfophenyl)theophylline (8-SPT) or the adenosine A2 antagonist 3,7-dimethyl-l-propargylxanthine (DMPX). Epinephrine (500 microg) was then administered, and intraocular pressures (IOPs), pupil diameters (PDs), or total outflow facility was evaluated. In a separate group of animals, epinephrine or vehicle was administered, and aqueous humor samples obtained to evaluate changes in aqueous humor purine levels by means of high-performance liquid chromatography.
In control animals, epinephrine produced a biphasic change in IOP: an initial rise in IOP of approximately 1 mm Hg from 1/2 to 1 hour followed by significant reduction in IOP of 8 to 9 mm Hg from 3 to 5 hours postadministration. These animals also exhibited a significant increase in PD of 2 to 3 mm from 1/2 to 2 hours postadministration. Pretreatment with 8-SPT (1000 microg) enhanced the initial rise in IOP, while significantly inhibiting the ocular hypotensive response. Pretreatment with 8-SPT also significantly enhanced the epinephrine-induced increase in PD. Inhibition of the epinephrine-induced reduction in IOP by 8-SPT was dose-related with an IC50 of 446 microg. Administration of 8-SPT alone did not significantly alter IOP or PD. The A2 antagonist DMPX did not alter the epinephrine-induced change in IOP or PD. In rabbits pretreated with 8-SPT, the epinephrine-induced increase in outflow facility was significantly reduced by 60% when compared with those in rabbits treated with epinephrine alone. In vehicle-treated rabbits, aqueous humor adenosine and inosine levels were 2.7 +/- 0.38 and 29 +/- 4.2 ng/100 microl, respectively. Three hours after epinephrine administration, adenosine and inosine levels had significantly increased to 11 +/- 1.6 and 66 +/- 4.4 ng/100 microl, respectively.
These results support the idea that in rabbits epinephrine administration stimulates adenosine release in the anterior segment. This rise in endogenous levels of adenosine then leads to the activation of ocular adenosine receptors and is in part responsible for the ocular hypotensive action of epinephrine.
肾上腺素是一种治疗青光眼的有效药物。然而,该化合物降低眼压作用的机制尚未完全明确。腺苷是一种由所有细胞释放的自分泌物质。本研究评估了腺苷受体激活在肾上腺素引起的眼功能变化中的作用。
给兔子局部预处理中等选择性的腺苷A1拮抗剂8 -(对磺基苯基)茶碱(8 - SPT)或腺苷A2拮抗剂3,7 - 二甲基 - 1 - 炔丙基黄嘌呤(DMPX)。然后给予肾上腺素(500微克),并评估眼压(IOP)、瞳孔直径(PD)或总房水流出率。在另一组动物中,给予肾上腺素或赋形剂,并采集房水样本,通过高效液相色谱法评估房水嘌呤水平的变化。
在对照动物中,肾上腺素引起眼压的双相变化:给药后1/2至1小时眼压初始升高约1毫米汞柱,随后在给药后3至5小时眼压显著降低8至9毫米汞柱。这些动物在给药后1/2至2小时瞳孔直径也显著增加2至3毫米。用8 - SPT(1000微克)预处理可增强眼压的初始升高,同时显著抑制降压反应。用8 - SPT预处理还显著增强了肾上腺素引起的瞳孔直径增加。8 - SPT对肾上腺素引起的眼压降低的抑制作用呈剂量依赖性,IC50为446微克。单独给予8 - SPT不会显著改变眼压或瞳孔直径。A2拮抗剂DMPX不会改变肾上腺素引起的眼压或瞳孔直径变化。在用8 - SPT预处理的兔子中,与单独用肾上腺素治疗的兔子相比,肾上腺素引起的房水流出率增加显著降低了60%。在用赋形剂治疗的兔子中,房水腺苷和肌苷水平分别为2.7±0.38和29±4.2纳克/100微升。肾上腺素给药3小时后,腺苷和肌苷水平分别显著增加至11±1.6和66±4.4纳克/100微升。
这些结果支持以下观点,即在兔子中,给予肾上腺素会刺激眼前节腺苷释放。内源性腺苷水平的升高进而导致眼腺苷受体的激活,这部分是肾上腺素降压作用的原因。